Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12473180 | 1.00 | KCNH2 (0.40) | KCNH2EPHX2DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL6584562 | 0.98 | KCNH2 (0.39) | KCNH2EPHX2DRD2DRD4DRD3 | |
| SCHEMBL26455030 | 0.94 | KCNH2 (0.36) | KCNH2EPHX2DRD2DRD4DRD3 | |
| SCHEMBL24634067 | 0.86 | KCNH2 (0.38) | KCNH2EPHX2DRD2DRD4DRD3 | |
| SCHEMBL26041000 | 0.86 | KCNH2 (0.38) | KCNH2EPHX2DRD2DRD4DRD3 | |
| SCHEMBL24634053 | 0.86 | KCNH2 (0.38) | KCNH2EPHX2DRD2DRD4DRD3 | |
| SCHEMBL25042763 | 0.82 | KCNH2 (0.52) | KCNH2DRD2DRD4DRD3EPHX1 | |
| SCHEMBL549384 | 0.82 | — | — | |
| SCHEMBL1142602 | 0.82 | KCNH2 (0.52) | KCNH2DRD2DRD4DRD3EPHX1 | |
| SCHEMBL14407749 | 0.81 | KCNH2 (0.40) | KCNH2DRD2DRD4DRD3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220111367-A1 | HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-14 | — | — | US | disclosed |
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-16 | — | — | US | disclosed |
| US-9849135-B2 | USP14 inhibitors for treating or preventing viral infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2528911-B1 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2014116228-A1 | USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011094545-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PSMG3, PSME3, PSMB11 | KCNH2 4198/4885EPHX2 4339/4885DRD2 4718/4885 |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | KCNH2 1394/4885EPHX2 3342/4885DRD2 4244/4885 |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSMB11, PSME3 | KCNH2 4222/4885EPHX2 4371/4885DRD2 4694/4885 |
| US-20220111367-A1 | HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME | SUV39H2, SUV39H1, HRH3 | KCNH2 1336/4885EPHX2 2175/4885DRD2 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.